Annual Total Liabilities
$5.15 B
+$911.60 M+21.51%
December 31, 2023
Summary
- As of February 12, 2025, VRTX annual total liabilities is $5.15 billion, with the most recent change of +$911.60 million (+21.51%) on December 31, 2023.
- During the last 3 years, VRTX annual total liabilities has risen by +$2.08 billion (+68.02%).
- VRTX annual total liabilities is now at all-time high.
Performance
VRTX Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Total Liabilities
$6.61 B
+$1.25 B+23.37%
September 30, 2024
Summary
- As of February 12, 2025, VRTX quarterly total liabilities is $6.61 billion, with the most recent change of +$1.25 billion (+23.37%) on September 30, 2024.
- Over the past year, VRTX quarterly total liabilities has increased by +$1.24 billion (+23.06%).
- VRTX quarterly total liabilities is now at all-time high.
Performance
VRTX Quarterly Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Total Liabilities Formula
Total Liabilities = Current Liabilities + Long-Term Liabilities
VRTX Total Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +21.5% | +23.1% |
| 3 y3 years | +68.0% | +23.1% |
| 5 y5 years | +184.4% | +195.9% |
VRTX Total Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +54.5% | at high | +98.3% |
| 5 y | 5-year | at high | +130.6% | at high | +195.9% |
| alltime | all time | at high | >+9999.0% | at high | >+9999.0% |
Vertex Pharmaceuticals Incorporated Total Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $6.61 B(+23.4%) |
| Jun 2024 | - | $5.36 B(-0.2%) |
| Mar 2024 | - | $5.37 B(+4.3%) |
| Dec 2023 | $5.15 B(+21.5%) | $5.15 B(-1.2%) |
| Sep 2023 | - | $5.21 B(+6.9%) |
| Jun 2023 | - | $4.88 B(+7.4%) |
| Mar 2023 | - | $4.54 B(+7.2%) |
| Dec 2022 | $4.24 B(+27.2%) | $4.24 B(+15.3%) |
| Sep 2022 | - | $3.68 B(+0.8%) |
| Jun 2022 | - | $3.65 B(+8.9%) |
| Mar 2022 | - | $3.35 B(+0.5%) |
| Dec 2021 | $3.33 B(+8.7%) | $3.33 B(+7.9%) |
| Sep 2021 | - | $3.09 B(+2.1%) |
| Jun 2021 | - | $3.03 B(-3.5%) |
| Mar 2021 | - | $3.13 B(+2.3%) |
| Dec 2020 | $3.06 B(+37.2%) | $3.06 B(-3.3%) |
| Sep 2020 | - | $3.17 B(+17.5%) |
| Jun 2020 | - | $2.70 B(+10.9%) |
| Mar 2020 | - | $2.43 B(+8.9%) |
| Dec 2019 | $2.23 B(+23.3%) | $2.23 B(-1.2%) |
| Sep 2019 | - | $2.26 B(+15.2%) |
| Jun 2019 | - | $1.96 B(+7.9%) |
| Mar 2019 | - | $1.82 B(+0.5%) |
| Dec 2018 | $1.81 B(+20.4%) | $1.81 B(+7.4%) |
| Sep 2018 | - | $1.69 B(+4.1%) |
| Jun 2018 | - | $1.62 B(+6.5%) |
| Mar 2018 | - | $1.52 B(+1.2%) |
| Dec 2017 | $1.50 B(-3.5%) | $1.50 B(+7.8%) |
| Sep 2017 | - | $1.40 B(-1.6%) |
| Jun 2017 | - | $1.42 B(+12.2%) |
| Mar 2017 | - | $1.26 B(-18.9%) |
| Dec 2016 | $1.56 B(+10.9%) | $1.56 B(+11.2%) |
| Sep 2016 | - | $1.40 B(+1.5%) |
| Jun 2016 | - | $1.38 B(+0.6%) |
| Mar 2016 | - | $1.37 B(-2.4%) |
| Dec 2015 | $1.40 B(+13.4%) | $1.40 B(+3.5%) |
| Sep 2015 | - | $1.36 B(+2.4%) |
| Jun 2015 | - | $1.33 B(+13.5%) |
| Mar 2015 | - | $1.17 B(-5.7%) |
| Dec 2014 | $1.24 B(+28.7%) | $1.24 B(-0.9%) |
| Sep 2014 | - | $1.25 B(+32.2%) |
| Jun 2014 | - | $945.55 M(-2.1%) |
| Mar 2014 | - | $966.23 M(+0.4%) |
| Dec 2013 | $962.64 M(-38.4%) | $962.64 M(-15.2%) |
| Sep 2013 | - | $1.14 B(+5.7%) |
| Jun 2013 | - | $1.07 B(-26.1%) |
| Mar 2013 | - | $1.45 B(-7.0%) |
| Dec 2012 | $1.56 B(+22.5%) | $1.56 B(+7.5%) |
| Sep 2012 | - | $1.45 B(+6.8%) |
| Jun 2012 | - | $1.36 B(+9.8%) |
| Mar 2012 | - | $1.24 B(-2.8%) |
| Dec 2011 | $1.28 B(+4.4%) | $1.28 B(-6.3%) |
| Sep 2011 | - | $1.36 B(+3.6%) |
| Jun 2011 | - | $1.31 B(+14.6%) |
| Mar 2011 | - | $1.15 B(-6.1%) |
| Dec 2010 | $1.22 B(+42.2%) | $1.22 B(-1.4%) |
| Sep 2010 | - | $1.24 B(+49.8%) |
| Jun 2010 | - | $827.07 M(+6.1%) |
| Mar 2010 | - | $779.69 M(-9.2%) |
| Dec 2009 | $859.14 M(+15.8%) | $859.14 M(-10.9%) |
| Sep 2009 | - | $964.75 M(+35.7%) |
| Jun 2009 | - | $710.82 M(-17.3%) |
| Mar 2009 | - | $859.03 M(+15.8%) |
| Dec 2008 | $741.61 M(+124.6%) | $741.61 M(+3.3%) |
| Sep 2008 | - | $717.66 M(-1.8%) |
| Jun 2008 | - | $730.88 M(+24.9%) |
| Mar 2008 | - | $585.25 M(+77.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2007 | $330.18 M(-20.6%) | $330.18 M(+2.2%) |
| Sep 2007 | - | $323.11 M(-6.7%) |
| Jun 2007 | - | $346.49 M(+3.8%) |
| Mar 2007 | - | $333.80 M(-19.7%) |
| Dec 2006 | $415.64 M(+34.2%) | $415.64 M(+5.4%) |
| Sep 2006 | - | $394.34 M(-12.5%) |
| Jun 2006 | - | $450.48 M(+54.4%) |
| Mar 2006 | - | $291.75 M(-5.8%) |
| Dec 2005 | $309.82 M(-39.3%) | $309.82 M(-25.7%) |
| Sep 2005 | - | $417.26 M(-12.0%) |
| Jun 2005 | - | $473.94 M(-3.8%) |
| Mar 2005 | - | $492.72 M(-3.4%) |
| Dec 2004 | $510.01 M(-4.1%) | $510.01 M(+2.0%) |
| Sep 2004 | - | $500.04 M(-2.7%) |
| Jun 2004 | - | $513.76 M(+0.3%) |
| Mar 2004 | - | $512.09 M(-3.7%) |
| Dec 2003 | $531.57 M(+21.6%) | $531.57 M(+3.9%) |
| Sep 2003 | - | $511.39 M(+7.9%) |
| Jun 2003 | - | $473.94 M(+7.7%) |
| Mar 2003 | - | $440.04 M(+0.7%) |
| Dec 2002 | $437.14 M(-2.8%) | $437.14 M(+3.4%) |
| Sep 2002 | - | $422.86 M(-0.2%) |
| Jun 2002 | - | $423.79 M(-0.4%) |
| Mar 2002 | - | $425.40 M(-5.4%) |
| Dec 2001 | $449.78 M(+5.3%) | $449.78 M(+0.8%) |
| Sep 2001 | - | $446.08 M(+15.7%) |
| Jun 2001 | - | $385.49 M(+1.8%) |
| Mar 2001 | - | $378.84 M(-11.3%) |
| Dec 2000 | $427.13 M(+1740.2%) | $427.13 M(-22.1%) |
| Sep 2000 | - | $547.96 M(+169.7%) |
| Jun 2000 | - | $203.21 M(+4.1%) |
| Mar 2000 | - | $195.19 M(+741.0%) |
| Dec 1999 | $23.21 M(+15.5%) | $23.21 M(+26.8%) |
| Sep 1999 | - | $18.30 M(-8.5%) |
| Jun 1999 | - | $20.00 M(-1.0%) |
| Mar 1999 | - | $20.20 M(+0.5%) |
| Dec 1998 | $20.10 M(+2.6%) | $20.10 M(+6.9%) |
| Sep 1998 | - | $18.80 M(+20.5%) |
| Jun 1998 | - | $15.60 M(+4.7%) |
| Mar 1998 | - | $14.90 M(-24.0%) |
| Dec 1997 | $19.60 M(+54.3%) | $19.60 M(+14.0%) |
| Sep 1997 | - | $17.20 M(+17.0%) |
| Jun 1997 | - | $14.70 M(+2.1%) |
| Mar 1997 | - | $14.40 M(+13.4%) |
| Dec 1996 | $12.70 M(-7.3%) | $12.70 M(+29.6%) |
| Sep 1996 | - | $9.80 M(-18.3%) |
| Jun 1996 | - | $12.00 M(+0.8%) |
| Mar 1996 | - | $11.90 M(-13.1%) |
| Dec 1995 | $13.70 M(+28.0%) | $13.70 M(+7.9%) |
| Sep 1995 | - | $12.70 M(-7.3%) |
| Jun 1995 | - | $13.70 M(+25.7%) |
| Mar 1995 | - | $10.90 M(+1.9%) |
| Dec 1994 | $10.70 M(-7.0%) | $10.70 M(-10.8%) |
| Sep 1994 | - | $12.00 M(+6.2%) |
| Jun 1994 | - | $11.30 M(+20.2%) |
| Mar 1994 | - | $9.40 M(-18.3%) |
| Dec 1993 | $11.50 M(+62.0%) | $11.50 M(+12.7%) |
| Sep 1993 | - | $10.20 M(+21.4%) |
| Jun 1993 | - | $8.40 M(+3.7%) |
| Mar 1993 | - | $8.10 M(+14.1%) |
| Dec 1992 | $7.10 M(+44.9%) | $7.10 M(+10.9%) |
| Sep 1992 | - | $6.40 M(+8.5%) |
| Jun 1992 | - | $5.90 M(+20.4%) |
| Mar 1992 | - | $4.90 M(0.0%) |
| Dec 1991 | $4.90 M(+22.5%) | $4.90 M(+6.5%) |
| Sep 1991 | - | $4.60 M(-2.1%) |
| Jun 1991 | - | $4.70 M(+17.5%) |
| Dec 1990 | $4.00 M | $4.00 M |
FAQ
- What is Vertex Pharmaceuticals Incorporated annual total liabilities?
- What is the all time high annual total liabilities for Vertex Pharmaceuticals Incorporated?
- What is Vertex Pharmaceuticals Incorporated annual total liabilities year-on-year change?
- What is Vertex Pharmaceuticals Incorporated quarterly total liabilities?
- What is the all time high quarterly total liabilities for Vertex Pharmaceuticals Incorporated?
- What is Vertex Pharmaceuticals Incorporated quarterly total liabilities year-on-year change?
What is Vertex Pharmaceuticals Incorporated annual total liabilities?
The current annual total liabilities of VRTX is $5.15 B
What is the all time high annual total liabilities for Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated all-time high annual total liabilities is $5.15 B
What is Vertex Pharmaceuticals Incorporated annual total liabilities year-on-year change?
Over the past year, VRTX annual total liabilities has changed by +$911.60 M (+21.51%)
What is Vertex Pharmaceuticals Incorporated quarterly total liabilities?
The current quarterly total liabilities of VRTX is $6.61 B
What is the all time high quarterly total liabilities for Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated all-time high quarterly total liabilities is $6.61 B
What is Vertex Pharmaceuticals Incorporated quarterly total liabilities year-on-year change?
Over the past year, VRTX quarterly total liabilities has changed by +$1.24 B (+23.06%)